ArticleTransplantation2000
Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging.
Article in Transplantation, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 84 citations in OpenAlex.
- Recurrent and De Novo Cirrhosis After Liver Transplantation.Portal hypertension & cirrhosis · 2026Article
- An Approach to Antibody-Mediated Rejection in Pediatric Liver Transplantation.Pediatric transplantation · 2026Review
- Fibrosis in One-Year Protocol Biopsies After Liver Transplantation Is Associated With Graft Loss: A Multicenter Cohort Study.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
- Navigating liver transplantation after malabsorptive bariatric surgery: A new risk of rejection.World journal of transplantation · 2026Article
- Animal models for transplant immunology: bridging bench to bedside.Clinical transplantation and research · 2024Review
- Immunology demystified: A guide for transplant hepatologists.World journal of transplantation · 2024Review
- Evaluation and management of abnormal liver enzymes in the liver transplant recipient: When, why, and what now?Clinical liver disease · 2023Review
- Chronic rejection after liver transplantation: Opening the Pandora's box.World journal of gastroenterology · 2021Article
- The Immunological Basis of Liver Allograft Rejection.Frontiers in immunology · 2020Review
- An Evaluation of the Usefulness of Extracorporeal Liver Support Techniques in Patients Hospitalized in the ICU for Severe Liver Dysfunction Secondary to Alcoholic Liver Disease.Hepatitis monthly · 2016Article
- Analysis of adult 20-year survivors after liver transplantation.Hepatology international · 2015Article
- Study of relationship between the blood supply of the extrahepatic bile duct and duct supply branches from gastroduodenal artery on imaging and anatomy.Chinese medical journal · 2015Article
- Abnormal Localization of STK17A in Bile Canaliculi in Liver Allografts: An Early Sign of Chronic Rejection.PloS one · 2015Article
- Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation.Digestive diseases and sciences · 2012Review
- Zinc finger protein A20 protects rats against chronic liver allograft dysfunction.World journal of gastroenterology · 2012Article
- Muromonab-CD3 for the successful treatment of early chronic rejection after pediatric liver transplantation: report of a case.Surgery today · 2011Article
- Cardiac allograft vasculopathy and insulin resistance--hope for new therapeutic targets.Endocrinology and metabolism clinics of North America · 2007Review
- Biliary wound healing, ductular reactions, and IL-6/gp130 signaling in the development of liver disease.World journal of gastroenterology · 2006Review
- Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence.Transplantation · 2001Article
- Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPredisposing factors, long-term occurrence, and histopathological changes associated with recovery or progression to allograft failure from chronic rejection (CR) were studied in adult patients treated primarily with tacrolimus.
methodsCR cases were identified using stringent criteria applied to a retrospective review of computerized clinicopathological data and slides.
resultsAfter 1973 days median follow-up, 35 (3.3%) of 1049 primary liver allograft recipients first developed CR between 16 and 2532 (median 242) days. The most significant risk factors for CR were the number (P<0.001) and histological severity (P<0.005) of acute rejection episodes and donor age >40 years (P<0.03). Other demographic and matching parameters were not associated with CR in this cohort. Ten patients died with, but not of, CR. Eight required retransplantation because of CR at a median of 268 days. Ten resolved either histologically or by normalization of liver injury tests over a median of 548 days. CR persisted for 340 to 2116 days in the remaining seven patients. More extensive bile duct loss (P<0.01), smallarterial loss (P<0.03), foam cell clusters (P<0.01) and higher total bilirubin (P<0.02) and aspartate aminotransferase (P<0.03) were associated with allograft failure from CR.
conclusionsEarly chronic liver allograft rejection is potentially reversible and a combination of histological, clinical, and laboratory data can be used to stage CR. Unique immunological and regenerative properties of liver allografts, which lead to a low incidence and reversibility of early CR, can provide insights into transplantation biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.